Occurrence of carcinoembryonic antigen in tumor tissue and serum of breast cancer patients.

In 116 breast cancer patients, the levels of carcinoembryonic antigen (CEA) were determined before operation in the serum using RIA, and after operation in sections of breast tumor tissue using the immunohistological PAP technique. CEA circulating in the serum was found in 49 patients (42%). Elevated values (over 10 micrograms/l) were found in only 12 patients (10%).

A non-competitive enzyme immunoassay of human alpha-lactalbumin in biological fluids and tissue extracts.

A sandwich non-competitive enzyme immunoassay for the measurement of human alpha-lactalbumin in serum, milk, and tumour tissue cytosol was developed using affinity-purified polyclonal antibody adsorbed to solid phase. The detection limits of this procedure in tubes (macromethod) and in wells of microtitre plates (micromethod) are 50 pg and 25 pg/sample, respectively, which means 2.5 micrograms/l of serum at appropriate dilution.

Three-year follow-up of carcinoembryonal antigen levels in the serum of patients with breast cancer.

The levels of carcinoembryonal antigen (CEA) were followed up for three years in 66 patients with breast cancer. In the group of patients treated surgically (N = 36, T1-2, NO-2, MO) the values of CEA were in agreement with the clinical course in 97% of the patients (35 out of 36 patients). Recurrence and/or dissemination of the disease were signalled by a rise in the serum CEA level to more than 15 micrograms/1 out four out of five patients more than 3-10 months before clinical manifestation.